{
    "clinical_study": {
        "@rank": "119487", 
        "acronym": "CXL", 
        "arm_group": [
            {
                "arm_group_label": "antibiotic treatment alone", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Crosslinking + Antibiotic", 
                "arm_group_type": "Experimental", 
                "description": "The procedure of the cross linking is standard:combined riboflavin(Ricrolin\u00ae)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.\nPatients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
            }
        ], 
        "brief_summary": {
            "textblock": "The corneal collagen cross linking is currently used in the treatment of keratoconus but\n      this procedure has also a sterilizing non-specific effect on bacteria and fungus. So the\n      corneal cross linking in association with the antibiotic treatment could result in a\n      reduction of the duration of epithelial complete healing of the cornea."
        }, 
        "brief_title": "Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bacterial Keratitis", 
            "Fungal Keratitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Communicable Diseases", 
                "Infection", 
                "Keratitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Infectious bacterial or fungal keratitis with : size > 2mm or within the central\n             corneal area ( 3mm of the visual axis ) or with a reaction in anterior chamber.\n\n          -  Being major responsible.\n\n          -  Agreement in writing to participate in the study.\n\n          -  Being affiliated to a national insurance scheme.\n\n        Exclusion Criteria:\n\n          -  Present an infectious keratitis without all the previous criteria.\n\n          -  Herpes or acanthamoeba keratitis\n\n          -  preperforated or perforated cornea.\n\n        General criteria:\n\n          -  Pregnant woman.\n\n          -  Minors(miners).\n\n          -  Adults under guardianship.\n\n          -  Patient can not be followed during 3 necessary months.\n\n          -  French speaking patient.\n\n          -  Unaffiliated patient in a national insurance scheme.\n\n          -  HIV infected patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088970", 
            "org_study_id": "RC14_0004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Crosslinking + Antibiotic", 
                "description": "The procedure of the cross linking is standard:combined riboflavin(Ricrolin\u00ae)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.\nPatients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation.", 
                "intervention_name": "Crosslinking", 
                "intervention_type": "Device", 
                "other_name": [
                    "Riboflavine 0,1%.", 
                    "Ricrolin.", 
                    "CE 0037.", 
                    "m\u00e9dical device class IIb.", 
                    "Manufacter : SOOFT Distributor : Horus pharma.", 
                    "transmitter UV-A :", 
                    "Model : Vega, CBM X Linker. (CSO, Florence, Italie)"
                ]
            }, 
            {
                "arm_group_label": [
                    "antibiotic treatment alone", 
                    "Crosslinking + Antibiotic"
                ], 
                "description": "If not the contact lens wearer -> Cocci Gram positive cocci\nVancomycin + Fortum\nIf contact lens wearer -> Gram negative bacillus\nFortum + Amiklin\nIf corticosteroids, immunosuppression, latent evolution -> Fungus.\n= Fortum + vancomycin + Fungizone", 
                "intervention_name": "antibiotic treatment", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular", 
                "Riboflavin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Infectious keratitis", 
            "Corneal cross linking", 
            "Topical antibiotics"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "isabelle.orignac@chu-nantes.fr", 
                "last_name": "Isabelle Orignac, PH", 
                "phone": "02 40 08 34 05"
            }, 
            "facility": {
                "address": {
                    "city": "Nantes", 
                    "country": "France", 
                    "zip": "44000"
                }, 
                "name": "Orignac"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study.", 
        "overall_contact": {
            "email": "isabelle.orignac@chu-nantes.fr", 
            "last_name": "Isabelle Orignac, PH", 
            "phone": "02 40 08 34 05"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Duration of corneal complete epithelial healing in days.", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088970"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Size of the corneal scar at 3months  expressed in % of the initial size of the corneal ulcer.", 
                "measure": "Size of the corneal scar", 
                "safety_issue": "No", 
                "time_frame": "3months"
            }, 
            {
                "description": "Corneal thinning estimated by Anterior segment optical coherence tomography at 3 months, expressed in microns.", 
                "measure": "Corneal thinning", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Gain of visual acuity, corresponding to the difference between the initial visual acuity and the 3months one. The visual acuity is measured with monoyer scale and converted in log Mar.", 
                "measure": "Gain of visual acuity", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}